🌍·14h agodiscovery
Kelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpoint
Publisher
P
PR Newswire
Global
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- PR Newswire
- Region
- Global
- Scope
- discovery
- Published
- July 15, 2026
- Language
- EN
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on news.google.com
Leave the platform to read the original full article on the publisher site.
Source: PR Newswire
Scope: discovery
Related coverage
More related coverage
UK Department of Health and Social Care/2h ago
British Sign Language (BSL) 5-year plan: Department of Health and Social Care
This plan sets out how the Department of Health and Social Care plans to improve the use of BSL in i...
medwatch.com/2h ago
Johnson & Johnson shares fall despite better-than-expected results
marketscreener.com/2h ago
Sichuan Kelun-Biotech Biopharmaceutical and Harbour Biomed Receive Nmpa Approval of Ind Application for Skb575/Hbm7575 for the Treatment of Asthma
The Pharma Letter/2h ago